Conclusion
This study shows that, based on the current evidence, PD-1/PD-L1 inhibitors alone can improve the OS of patients with recurrent/metastatic head and neck squamous cell carcinoma, without serious adverse reactions, but the ORR still needs to be improved. In future research, the combination of drugs and new adjuvant treatments will help immunotherapy play a better role in the treatment of HNSCC.